PRIMA Retinal Implant: Europe Approves a Vision-Restoring System for Macular Degeneration
Age-related macular degeneration (AMD) affects more than 5 million people worldwide, and until now nothing could bring back the central vision it destroys. The Prima system pairs a retinal implant with camera-equipped glasses, and it was approved in Europe in July. A US decision from the FDA is still pending. If it clears, it would be the first device of its kind to move from research into routine eye care for a large patient group.
What Prima actually is
Prima is a two-part system. A small camera mounted on a pair of glasses captures the scene in front of the wearer. That information is sent to a tiny implant placed under the retina, where it is converted into electrical stimulation of the nerve cells that remain.
As publicly described, the glasses transmit the image using near-infrared light, so the implant needs no external wiring through the eye. The design targets the macula, the central region of the retina. The patient's own peripheral vision is left to do its normal job.
Why AMD has been so hard to treat
AMD gradually destroys the macula, the part of the eye responsible for reading, recognizing faces, and driving. The existing toolkit is built around slowing damage. Anti-VEGF injections are the standard for the wet form of the disease, and in the US, drugs that slow progression of geographic atrophy, an advanced dry form, were approved in recent years.
Those therapies preserve what a patient still has. None of them replace photoreceptors that have already died. That is the gap Prima is aimed at, and it is why the combination of implant and glasses matters more than another incremental drug.
How this fits the earlier Prima story
We covered an earlier milestone in Science Corporation PRIMA Retinal Implant: First Stargardt Disease Patient and the Path to BCI, when Max Hodak described the chip as part of a route toward a new brain-computer interface. That story was about a rare disease and a long-term platform vision. This one is about a regulatory approval for a far more common condition, which is a different kind of proof: not whether the technology works in principle, but whether a regulator will let it be sold.
Why it matters beyond one device
The first point is market size. A condition affecting millions of older adults is a very different commercial and clinical proposition from a rare inherited disease. Hospitals, insurers, and device makers will have to think about surgical capacity, training, and long-term follow-up at a scale they have not needed for retinal prostheses before.
The second point is the comparison with earlier retinal implants. Previous devices were generally aimed at patients with severe vision loss from other diseases and offered limited, low-resolution perception. Prima shows that a prosthesis can be considered for the central vision loss typical of AMD. How good the restored vision is compared with natural sight will be the key question for patients, and the answer is unlikely to be "the same."
The third point is the signal for neurotechnology. Prima's developer has openly framed its work as a stepping stone toward broader brain-computer interfaces. A regulator-approved implant that talks to neural tissue gives the sector a real-world reference for safety, surgery, and patient training.
What to watch next
Three things will decide how far this goes. The first is the FDA decision, which would open the largest single market. The second is pricing and reimbursement: an implant that is approved but not covered by insurers will reach few patients. The third is long-term data on how the implant holds up over years inside the eye.
It is reasonable to expect a gradual rollout, starting at specialist centers, because surgery and rehabilitation training need experienced teams. That is a forecast, not an announced plan.
Takeaway
Prima does not cure AMD, and it will not return normal eyesight. What it does is offer, for the first time, a route to regaining some usable central vision once the disease has already taken it. The European approval makes that route real, and the US decision will show whether it becomes standard care.
Comments
Post a Comment
Please read our comment policy before commenting.